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Abstract 
Objective: The objective of this selective EBM review is to determine whether or not “Submental 
deoxycholic acid injections reduce submental fat in adult patients enough to create a significant increase 
in patient satisfaction”  
Study Design: Review of 3 double blind, randomized control trials that were selected based on their 
relevance to the clinical question.  
Data Sources: All three peer-reviewed articles were found using PubMed and Cochrane Database. The 
keywords “ATX-101”, “submental fat”, and “deoxycholic acid” were used.  
Outcomes Measured: Satisfaction with appearance in association with face and chin evaluated by a 
patient reported subject self-rating scale (PR-SSRS), a numeric scale with values from 0-6.  
Results: All three trials recorded significant improvement in subject satisfaction compared to placebo 
with a p-value <0.001. The REFINE-1 study showed had an NNT value of 2 with 82.8% of the treatment 
group showing improvement compared to 31.0% of the placebo group. Ascher et al had an NNT of 3. 
64.8% of the treatment group showed improvement with only 29.3% of the control group showing 
improvement. Finally, Rzany et al reported an NNT of 3. The treatment group had an improvement rate 
of 66.1% and the control group’s rate was only 28.7%. 
Conclusion: Deoxycholic acid injections to the submental region resulted in a consistent improvement in 
patients’ satisfaction with the appearance of their submental region. The NNT values are low proving 
these injections to be effective in improving satisfaction.  
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Introduction 
 Submental fat is considered by many to be aesthetically unappealing and its’ origin 
is multifactorial; stemming from obesity, genetics, and aging. The increasing fullness underneath 
the chin is almost always visible and can cause individuals significant social and psychological 
stress. The presence of submental fullness is associated with all races, genders, and has an 
increasing prevalence with age. Because of this trend, it is seen as a sign of aging and obesity. 
Blunting of the cervicomental angle produces a less pronounced jawline. These issues can cause 
a decrease in self-esteem.
1-3
  
 Currently there are a few options to decrease the fat below the chin. Surgical 
interventions, such as platysmaplasty (neck lift) and liposuction procedures currently exist. In 
addition there are also injectable treatments that are also available, however, these are currently 
unregulated and can be unsafe.
1-3
 In a 2015 survey by the American Society for Dermatologic 
Surgery 67% of the population reported to be extremely bothered by the excess fat under their 
chin/neck
4
. In 2015 the number of neck lifts performed in the United States was 32, 695 per the 
Interanational Society of Aesthetic Plastic Surgery. This does not include consultation visits and 
post-procedure visits . There were 119,470 procedures of non-surgical fat removal but this was 
not differentiated into body area. In addition, there were 1,805,895 injection procedures but 
again, this was not differentiated by injection site
5
.  
The exact cost for money spent on reduction of submental fat is not statistically available, 
however, the American Society for Aesthetic Plastic Surgery reports that total expenditures for 
surgical chin augmentation in 2012 was $26,623,143. This is not including the costs for 
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liposuction and other non-surgical injectables. Overall in 2012 Americans spent over $10 billion 
for cosmetic procedures in 2012.
6 
 
 Deoxycholic acid is a substance that causes adipocytes to lyse by disrupting their 
membrane. This method is seen to be much safer than surgical interventions that can lead to long 
recovery times and increased rate of infections. The surgical procedures can also leave an 
aesthetic deformity. The currently used injectables have no documented efficacy, so deoxycholic 
acid has been proposed as a safe, effective way to reduce submental fat
1,2,3
.  
Objective 
 The objective of this selective EBM review is to determine whether or not 
“submental deoxycholic acid injections reduce submental fat in adult patients enough to create a 
significant increase in patient satisfaction” 
Methods 
 The population of patients used in the studies in this review was adults aged 18-65. 
All of the adults were dissatisfied with the appearance of their submental region (0-3 on the 
patient reported submental fat rating scale) and they all were rated moderate to severe submental 
fat (2-3 on the clinician reported submental fat rating scale). All of the studies tested the efficacy 
and the safety of deoxycholic acid injections into the submental region. Each individual injection 
was 0.2mL with a max dose of 10mL per patient per treatment. Some of the studies included two 
treatment groups, one with a concentration of 1.0mg/cm
2
, and another with a concentration of 
2.0mg/cm
2
. A 1.0cm x 1.0cm grid was used to assure equal spacing of the injections. All trials 
compared the treatment group with a placebo injection group. The measured outcome that I have 
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reviewed from the trials is patient satisfaction of their submental appearance. All three articles 
were phase III, randomized, double-blind, placebo controlled clinical trials.  
 The key words used in searches were “ATX-101”, “Deoxycholic Acid”, and 
“Submental fat”. All articles were published in English and were found on PubMed and 
Cochrane databases. Inclusion criteria for my search were studies that were randomized, 
controlled, and double blind. Exclusion criteria included individuals younger than 18, individuals 
with minimal submental fat, and individuals who were already satisfied with their submental 
appearance. The statistics used in the trials included NNT, CER, EER, ABI, and RBI. 
Outcomes Measured 
 The outcome that was measured in all the studies that I focused on was the subject 
self-satisfaction rating (SSRS). I chose this outcome because it directly relates to how the patient 
felt about the treatment making it a POEM. The SSRS is a numeric scale from 0-6.  The value of 
0 was used for extremely dissatisfied, 1 for dissatisfied, 2 for slightly dissatisfied, 3 for neither 
satisfied nor dissatisfied, 4 for slightly satisfied, 5 for satisfied, and 6 for extremely satisfied. In 
these trials a person had to rate themselves 0-3 to be included. After treatment a value of 4-6 was 
considered a success. The studies also followed adverse effects reported by the study 
participants. The three most commonly reported adverse effects were bruising, anesthesia, and 
pain. Patients reported when these effects were experienced after each treatment.  
Results 
 The REFINE-1 study included 506 participants with 256 being randomized to the 
treatment group and the other 200 to placebo injection. All 506 participants were included in the  
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Table 1. Study Demographic
Study  Type  # 
Pts  
Age (yrs)  Inclusion Criteria  Exclusion Criteria  W 
/D  
Interventions  
Ascher 
(2013) 
6  
Double 
Blind 
RCT  
360  46±9.87  Men and non-pregnant, non-lactating 
women under medical birth control if of 
reproductive age were required to be 18-
65 years of age. Patients with moderate 
to severe (2-3) submental fat according 
to the clinician-reported submental fat 
rating scale (CR-SMFRS) who were 
dissatisfied (0-3 on the subject self-
rating scale) with their submental 
appearance were eligible.  
Individuals with a BMI >30kg/m 2 . 
Indiviuals with any significant abnormality in 
their clinical and laboratory evaluations. 
Patients with any of the following: previous 
submental fat treatments or recent aesthetic 
facial treatments; loose skin or previous 
trauma in the neck or chin area, prominent 
platysmal bands, any cause of enlargement in 
the submental area other than submental 
fat;patients currently on or considering 
starting a weight-reduction regimen, or 
sensitive to any components of the study.  
26  A maximum of 10mL 
of deoxycholic acid 
injected with 0.2mL 
injections injected 
1.0cm apart using a 
grid to provide even 
coverage.  
Jones 
(2015) 
4  
Double 
Blind 
RCT  
506  49.5±9.3  Men and women age of 18-65 years. 
Patients with moderate to severe (2-3) 
submental fat according to the clinician-
reported submental fat rating scale (CR-
SMFRS) who were dissatisfied (0-3 on 
the subject self-rating scale) with their 
submental appearance were eligible. 
Patients also need a BMI ≤40kg/m 2 and 
had a stable body weight for ≥6 months  
Subjects were excluded if they had excessive 
skin laxity or allergy/ hypersensitivity to the 
components of the study drug or topical/ local 
anesthetics; received treatment previously for 
submental fat or were treated in the neck/chin 
area with radiofrequency, lasers, chemical 
peels, or dermal fillers ≤12 months or 
botulinum toxin injections ≤ 6 months before 
randomization; or previously participated in 
ATX-101 trials  
0  A maximum of 10mL 
of deoxycholic acid 
injected with 0.2mL 
injections injected 
1.0cm apart using a 
grid to provide even 
coverage.  
Rzany 
(2013) 
5  
Double 
blind 
RCT  
363  46.4±10.2 
9  
Men and women age of 18-65 years. 
Patients with moderate to severe (2-3) 
submental fat according to the clinician-
reported submental fat rating scale (CR-
SMFRS) who were dissatisfied (0-3 on 
the subject self-rating scale) with their 
submental appearance were eligible. 
Patients also need a BMI ≤30 kg/m 2 .  
Previous intervention to treat submental fat, 
anatomical features or previous trauma; 
evidence of any cause of submental 
enlargement other than submental fat;. 
Patients with a history of sensitivity to any 
components of the study material or topical 
or local anesthetics were also exclueded  
34  A maximum of 10mL 
of deoxycholic acid 
injected with 0.2mL 
injections injected 
1.0cm apart using a 
grid to provide even 
coverage.  
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final analysis. Using the SSRS as the measured variable, those in the treatment group had a 
success rate of 82.8% compared to the placebo success rate of 31.0% (p-value<0.001). The NNT 
for this trial was 3. This study used a maximum of 6 different treatments spaced out 28±5 days. 
In the treatment group 164 individuals received all 6 treatments and 92 received less than six. 
The three biggest reasons that were given for withdrawal were insufficient submental fat (33), 
adverse effects (19), and withdrawal of consent due to subject convenience (14). In the control 
group 213 received all 6 treatments and 37 received less than 6.
1
  
 Ascher et al had 360 patients in the study. 117 patients were randomized to the 
placebo injection group. 122 were put into the treatment group with the concentration of 
2.0mg/cm
2
. This is the concentration that was consistent throughout all of the trials; therefore it 
was used for the purposes of this study. The treatment group had success on the SSRS with a rate 
of 64.8% compared to a placebo success rate of 29.3% (p-value<0.001). The NNT in this study 
was 3. This study looked at four treatment sessions spaced 28±5 days. In the injection group 32 
of the 122 withdrew from the study early. The most common reasons were adverse effects (14), 
consent withdrawn (10), and early success (6). 16 of the 117 in the placebo group withdrew from 
the study early.
2 
 The Rzany et al. study included 363 participants. There were 122  randomized to the 
placebo group. Another 121 were placed in the treatment group that received the 2.0mg/cm
2
 
concentration. 66.1% of the individuals in the treatment group were a success on the SSRS 
compared to 28.7% in the placebo group (p-value <0.001). This study also had a maximum of 4 
treatments spaced out 28±5 days. 34 of the 121 discontinued the treatment before receiving all 
four treatments. The most common reason was early therapeutic success (13), followed by 
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adverse effects (10), and withdrawal (7). 14 of the 122 participants in the placebo group 
discontinued prematurely.
3 
Table 2. SSRS Results 
Study 
Control Event 
Rate (CER) 
Experimental 
Event Rate 
(EER) 
Absolute Benefit 
increase (ABI) 
Relative Benefit 
Increase (RBI) 
Numbers 
Needed to Treat 
(NNT) 
REFINE-1
1 
31.0% 82.8% 167.1% 51.8% 2 
Ascher et al
2 
29.3% 64.8% 121.1% 35.5% 3 
Rzany et al
3 
28.7% 66.1% 130.3% 37.4% 3 
 
 Safety outcomes were recorded in each trial as adverse effects. The REFINE-1 study 
used clinician visual and tactile assessments of the submental region, as well as reports of 
adverse effects, laboratory tests (U/A, Chemistry, Hematology, and thyroid function, and vital 
signs. The studies by Ascher et al and Rzany et al used clinical evaluations and patient reports of 
adverse effects before and after each treatment to record safety outcomes. They also used 
unspecified clinical laboratory parameters. The NNH for the most common adverse effects of 
pain, bruising, and anesthesia are displayed in table 3.  
Table 3. Adverse Effects 
Study Bruising NNH Anesthesia NNH Pain NNH 
REFINE-1
1 
37 2 2 
Ascher
2 
10 2 2 
Rzany
3 
7 2 2 
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Discussion 
 The SSRS was chosen for this review because of its universal application in the 
studies and because it answers a simple question “did you go from unsatisfied to satisfied with 
the appearance of your submental region?” Using the SSRS all of the trials showed a statistically 
significant increase in the treatment groups compared to placebo. For the purposes of this review 
this variable was selected from all of the studies because it is patient oriented evidence that 
provides insight into exactly how the patients felt about the treatment. However, all of the studies 
had other outcomes that they measured. The other outcomes included a clinician evaluated 
submental fat convexity and patient evaluated submental fat rating. They also followed the 
psychological impact of submental fat appearance on feelings and perceived visual self-image 
using a standardized reporting scale. 
 Deoxycholic acid is currently being used under the brand name Kybella distributed 
by Kythera Biopharmaceuticals. This treatment is purely cosmetic and is an elective treatment; 
therefore virtually no insurance covers the cost. The actual out of pocket cost for patients  varies 
due to the individualized nature of the treatment. Patients with more submental fat could require 
more injections per treatment and more treatments overall which could inflate costs. The cost of 
treatment varies between providers and also between geographic regions. It’s not unreasonable to 
expect to spend several thousand dollars for all of the required treatments.  
 These trials all compared the deoxycholic acid injections to a placebo injection. A 
more potent comparison could be made by comparing different forms of treatment such as 
liposuction; however, this would have to be a comparison between two different subjects as one 
person would not be eligible for both treatments.  
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 The adverse effects were also reported significantly more in the treatment group 
compared to the control. All three trials however, reported that many of these effects were 
experienced during their first treatment and faded quickly. There were instances of dysphagia 
and facial paralysis reported by the trials, but they did not have a high enough incidence to be 
reported in the results (needed incidence ≥5%). The authors also reported that these effects were 
transient. 
CONCLUSION 
 The trials all had a significant increase in SSRS in the treatment groups compared to 
placebo. Therefore deoxycholic acid injections did decrease submental fat in a way to improve 
satisfaction with the submental region. The comparison between these injections and other 
modalities of reducing submental fullness has not been fully explored. Further research could be 
conducted to show a superior treatment, if one exists. Currently there are studies that are being 
done to evaluate the long term effectiveness of deoxycholic acid injections. Currently, however, 
these injections seem to be an effective and relatively safe method of reducing submental fat in 
individuals who wish to do so.  
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